Mathias Muth

536 total citations
22 papers, 431 citations indexed

About

Mathias Muth is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mathias Muth has authored 22 papers receiving a total of 431 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 9 papers in Molecular Biology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mathias Muth's work include Advanced Breast Cancer Therapies (7 papers), Bone health and treatments (7 papers) and Receptor Mechanisms and Signaling (5 papers). Mathias Muth is often cited by papers focused on Advanced Breast Cancer Therapies (7 papers), Bone health and treatments (7 papers) and Receptor Mechanisms and Signaling (5 papers). Mathias Muth collaborates with scholars based in Germany, United States and Italy. Mathias Muth's co-authors include Ulrike Holzgrabe, Klaus Mohr, Clelia Dallanoce, Marco De Amici, Simona Bertoni, Elisabetta Barocelli, Christian Tränkle, Evi Kostenis, Eberhard Heller and Hans‐Dieter Höltje and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The FASEB Journal.

In The Last Decade

Mathias Muth

22 papers receiving 422 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mathias Muth Germany	12	328	204	84	58	53	22	431
Yubo Cao China	10	255 0.8×	113 0.6×	54 0.6×	41 0.7×	22 0.4×	17	354
Percy Carter United States	4	215 0.7×	82 0.4×	97 1.2×	60 1.0×	5 0.1×	6	313
Catherine Bardelle United Kingdom	12	237 0.7×	96 0.5×	66 0.8×	12 0.2×	23 0.4×	20	395
Frederick A. Brookfield United Kingdom	10	187 0.6×	63 0.3×	42 0.5×	12 0.2×	48 0.9×	10	336
James R. Porter United States	8	350 1.1×	23 0.1×	59 0.7×	12 0.2×	49 0.9×	12	483
Louise Laursen Denmark	10	226 0.7×	71 0.3×	42 0.5×	80 1.4×	47 0.9×	14	385
Milos Matkovic Switzerland	6	264 0.8×	84 0.4×	90 1.1×	47 0.8×	11 0.2×	8	349
John Doran United States	10	343 1.0×	56 0.3×	83 1.0×	8 0.1×	58 1.1×	17	550
Dewei Tang United States	12	170 0.5×	44 0.2×	118 1.4×	120 2.1×	24 0.5×	22	375
Lenka Řihakova Canada	8	192 0.6×	66 0.3×	20 0.2×	21 0.4×	15 0.3×	17	329

Countries citing papers authored by Mathias Muth

Since Specialization

Citations

This map shows the geographic impact of Mathias Muth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mathias Muth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mathias Muth more than expected).

Fields of papers citing papers by Mathias Muth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mathias Muth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mathias Muth. The network helps show where Mathias Muth may publish in the future.

Co-authorship network of co-authors of Mathias Muth

This figure shows the co-authorship network connecting the top 25 collaborators of Mathias Muth. A scholar is included among the top collaborators of Mathias Muth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mathias Muth. Mathias Muth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hadji, Peyman, Oliver J. Stoetzer, Thomas Decker, et al.. (2018). The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial. Journal of bone oncology. 14. 100199–100199. 4 indexed citations

Tesch, Hans, Oliver J. Stoetzer, Thomas Decker, et al.. (2018). Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor‐positive, human epidermal growth factor receptor 2‐negative locally advanced or metastatic breast cancer: Results of the single‐arm, phase IIIB 4EVER trial. International Journal of Cancer. 144(4). 877–885. 31 indexed citations

Matera, Carlo, Andreas Böck, Mathias Muth, et al.. (2017). A New Molecular Mechanism To Engineer Protean Agonism at a G Protein–Coupled Receptor. Molecular Pharmacology. 91(4). 348–356. 11 indexed citations

Tesch, Hans, Oliver J. Stoetzer, Thomas Decker, et al.. (2015). Abstract P5-19-06: 4EVER - Final efficacy analysis of the phase IIIb, multi-center, open label study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer (BC) treated with everolimus (EVE) in combination with exemestane (EXE). Cancer Research. 75(9_Supplement). P5–19. 3 indexed citations

Jackisch, Christian, Eva‐Maria Grischke, Andreas Schneeweiß, et al.. (2015). Abstract P5-19-12: Subgroup analysis on efficacy in the routine treatment - Results of the 2nd interim analysis of BRAWO, the non-interventional trial "Breast Cancer Treatment with Everolimus and Exemestane for HR+ Women". Cancer Research. 75(9_Supplement). P5–19. 3 indexed citations

Hadji, Peyman, M. Ziller, Katrin Birkholz, et al.. (2014). Effect of adjuvant endocrine therapy on hormonal levels in premenopausal women with breast cancer: the ProBONE II study. Breast Cancer Research and Treatment. 144(2). 343–351. 12 indexed citations

Maass, Nicolaì, Christian Schem, Dirk Bauerschlag, et al.. (2014). Final Safety and Efficacy Analysis of a Phase I/II Trial with Imatinib and Vinorelbine for Patients with Metastatic Breast Cancer. Oncology. 87(5). 300–310. 12 indexed citations

Ziller, M., et al.. (2014). Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study. Osteoporosis International. 25(4). 1369–1378. 23 indexed citations

Schuetz, Florian, Eva‐Maria Grischke, Peter A. Fasching, et al.. (2014). Breast cancer treatment with everolimus and exemestane for ER+ women: Results of the first interim analysis of the noninterventional trial BRAWO.. Journal of Clinical Oncology. 32(15_suppl). 578–578. 2 indexed citations

10.

Böck, Andreas, Mathias Muth, Clelia Dallanoce, et al.. (2013). Dynamic ligand binding dictates partial agonism at a G protein–coupled receptor. Nature Chemical Biology. 10(1). 18–20. 44 indexed citations

11.

Fasching, Peter A., W. Gumbrecht, Tanja Fehm, et al.. (2013). 4EVER: Assessment of circulating tumor cells with a novel, filtration-based method, in a phase IIIb multicenter study for postmenopausal, HER2- negative, estrogen receptor-positive, advanced breast cancer patients.. Journal of Clinical Oncology. 31(15_suppl). 591–591. 3 indexed citations

12.

Hadji, Peyman, M. Ziller, Tobias Maurer, et al.. (2012). The ZOTECT study: Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer. Journal of bone oncology. 1(3). 88–94. 2 indexed citations

13.

Fasching, PA, Maik Hauschild, Sherko Kümmel, et al.. (2012). Abstract PD07-02: Anticancer activity of letrozole plus zoledronic acid as neoadjuvant therapy for postmenopausal patients with breast cancer: FEMZONE trial results. Cancer Research. 72(24_Supplement). PD07–2. 2 indexed citations

14.

Kalder, Matthias, Umberto Albert, Katrin Birkholz, et al.. (2011). P2-19-03: Influence of Zoledronic Acid on BMD in Premenopausal Women with Breast Cancer and Neoadjuvant or Adjuvant Chemotherapy and/or Endocrine Treatment – The ProBone Studies.. Cancer Research. 71(24_Supplement). P2–19. 1 indexed citations

15.

Kalder, Matthias, et al.. (2010). 14 Influence of zoledronic acid on bone mineral density in premenopausal women with hormone receptor positive or negative breast cancer and neoadjuvant or adjuvant chemotherapy or endocrine treatment. European Journal of Cancer Supplements. 8(3). 62–62. 1 indexed citations

16.

Muth, Mathias, Eberhard Heller, Clelia Dallanoce, et al.. (2008). Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity. The FASEB Journal. 23(2). 442–450. 128 indexed citations

17.

Muth, Mathias, Verena Hoerr, Alicia Ponte‐Sucre, et al.. (2007). Antitrypanosomal activity of quaternary naphthalimide derivatives. Bioorganic & Medicinal Chemistry Letters. 17(6). 1590–1593. 28 indexed citations

18.

Muth, Mathias, et al.. (2005). Muscarinic Allosteric Enhancers of Ligand Binding: Pivotal Pharmacophoric Elements in Hexamethonio-Type Agents. Journal of Medicinal Chemistry. 48(6). 2212–2217. 13 indexed citations

19.

Muth, Mathias, Clelia Dallanoce, Elisabetta Barocelli, et al.. (2005). Design, Synthesis, and Action of Oxotremorine-Related Hybrid-Type Allosteric Modulators of Muscarinic Acetylcholine Receptors. Journal of Medicinal Chemistry. 49(1). 366–372. 66 indexed citations

20.

Muth, Mathias, et al.. (2003). Systematic Development of High Affinity Bis(ammonio)alkane-type Allosteric Enhancers of Muscarinic Ligand Binding. Journal of Medicinal Chemistry. 46(6). 1031–1040. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact